Trial Profile
A prospective randomized trial of VP-16 plus G-CSF plus rituximab vs VP-16 plus G-CSF alone for peripheral blood progenitor cell mobilization prior to autologous stem cell transplantation for B cell lymphoid malignancies.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Etoposide (Primary) ; Filgrastim (Primary) ; Rituximab (Primary) ; Busulfan; Cyclophosphamide; Filgrastim
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 28 Mar 2011 Actual end date (May 2006) added as reported by ClinicalTrials.gov.
- 28 Mar 2011 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
- 28 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.